October 31st, 2010 by admin
VIVUS, Inc. (Nasdaq: VVUS) announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form… [...]
Read the rest »
October 25th, 2010 by admin
Citing cancer risks as one of its reasons, lorcaserin, an experimental drug for obesity treatment and maintenance of weight loss, was turned down by the Food and Drug Administration (FDA). The FDA informed lorcaserin makers, Arena Pharmaceuticals Inc… Related Blogs
Read the rest »
September 17th, 2010 by admin
A US Food and Drug Administration (FDA) advisory committee has voted against recommending federal approval of the new obesity drug lorcaserin, made by Arena Pharmaceuticals Inc under the brand name Lorqess, making it the third time this year that an obesity drug has failed to get the thumbs up from the panel… Related Blogs Obama [...]
Read the rest »